190 related articles for article (PubMed ID: 38195306)
1. Approach to High-Risk Multiple Myeloma.
Chen X; Varma G; Davies F; Morgan G
Hematol Oncol Clin North Am; 2024 Apr; 38(2):497-510. PubMed ID: 38195306
[TBL] [Abstract][Full Text] [Related]
2. [Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)].
;
Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):430-435. PubMed ID: 38964916
[TBL] [Abstract][Full Text] [Related]
3. Knowing the unknowns in high risk multiple myeloma.
Derman BA; Kosuri S; Jakubowiak A
Blood Rev; 2022 Jan; 51():100887. PubMed ID: 34479756
[TBL] [Abstract][Full Text] [Related]
4. Defining and Managing High-Risk Multiple Myeloma: Current Concepts.
Costa LJ; Usmani SZ
J Natl Compr Canc Netw; 2020 Dec; 18(12):1730-1737. PubMed ID: 33285523
[TBL] [Abstract][Full Text] [Related]
5. Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.
Talley PJ; Chantry AD; Buckle CH
Br Med Bull; 2015 Mar; 113(1):15-30. PubMed ID: 25662536
[TBL] [Abstract][Full Text] [Related]
6. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
7. Advances in the biology and therapeutic management of multiple myeloma.
Kaufmann H; Urbauer E; Ackermann J; Huber H; Drach J
Ann Hematol; 2001 Aug; 80(8):445-51. PubMed ID: 11563588
[TBL] [Abstract][Full Text] [Related]
8. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
Claudio JO; Stewart AK
Am J Pharmacogenomics; 2005; 5(1):35-43. PubMed ID: 15727487
[TBL] [Abstract][Full Text] [Related]
9. Staging and prognostication of multiple myeloma.
Fonseca R; Monge J; Dimopoulos MA
Expert Rev Hematol; 2014 Feb; 7(1):21-31. PubMed ID: 24483346
[TBL] [Abstract][Full Text] [Related]
10. Treatment of newly diagnosed multiple myeloma: advances in current therapy.
Kumar S
Med Oncol; 2010 Jun; 27 Suppl 1():S14-24. PubMed ID: 20035387
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: new aspects of biology and treatment.
Ozaki S; Kosaka M
J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: diagnosis and treatment.
Rajkumar SV; Kyle RA
Mayo Clin Proc; 2005 Oct; 80(10):1371-82. PubMed ID: 16212152
[TBL] [Abstract][Full Text] [Related]
13. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W
Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531
[TBL] [Abstract][Full Text] [Related]
14. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
Mikhael JR; Dingli D; Roy V; Reeder CB; Buadi FK; Hayman SR; Dispenzieri A; Fonseca R; Sher T; Kyle RA; Lin Y; Russell SJ; Kumar S; Bergsagel PL; Zeldenrust SR; Leung N; Drake MT; Kapoor P; Ansell SM; Witzig TE; Lust JA; Dalton RJ; Gertz MA; Stewart AK; Rajkumar SV; Chanan-Khan A; Lacy MQ;
Mayo Clin Proc; 2013 Apr; 88(4):360-76. PubMed ID: 23541011
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
16. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.
Baertsch MA; Lutz R; Raab MS; Weinhold N; Goldschmidt H
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2445-2455. PubMed ID: 31407112
[TBL] [Abstract][Full Text] [Related]
17. Moving Toward a Cure for Myeloma.
Mateos MV; Nooka AK; Larson SM
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35623025
[TBL] [Abstract][Full Text] [Related]
18. How to use new biology to guide therapy in multiple myeloma.
Morgan GJ; Kaiser MF
Hematology Am Soc Hematol Educ Program; 2012; 2012():342-9. PubMed ID: 23233602
[TBL] [Abstract][Full Text] [Related]
19. [Multiple myeloma: pathophysiology and progress in management].
Kuroda J; Chinen Y
Rinsho Ketsueki; 2017; 58(5):487-497. PubMed ID: 28592764
[TBL] [Abstract][Full Text] [Related]
20. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
Johnson SK; Heuck CJ; Albino AP; Qu P; Zhang Q; Barlogie B; Shaughnessy JD
Int J Hematol; 2011 Oct; 94(4):321-333. PubMed ID: 22002477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
